Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 9593066
Process to prepare treprostinil, the active ingredient in remodulin®
granted -
US 9593136
Compounds for inhibiting 1-deoxy-D-xylulose-5-phosphate reductoisomerase
granted -
US 9587232
Mutated organophosphorus acid anhydrolases and their uses thereof
granted -
US 9580492
Monoclonal antibodies that neutralize anthrax toxins
granted -
US 9579302
Ketone bodies to protect tissues from damage by ionizing radiation
granted -
US 9579333
Inhibition of HIV infection through chemoprophyalxis
granted -
US 9566329
Live, attenuated rubella vector to express vaccine antigens
granted -
US 9567387
T cell receptors and related materials and methods of use
granted -
US 9567566
HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
granted -
US 9561206
Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
granted -
US 9562237
Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
granted -
US 9556237
Antiviral rift valley fever virus peptides and methods of use
granted -
US 9555090
Equine encephalitis virus vaccines and methods of using thereof
granted -
US 9555064
Protease-deficient Bacillus anthracis
granted -
US 9556244
Vaccination of animals to elicit a protective immune response against tick infestations and tick-borne pathogen transmission
granted -
US 9554587
Anti-regurgitation composition maintaining gut motility
granted -
US 9550818
Methods for use of vascular endothelial growth factor antagonists
granted -
US 9549975
Genetically engineered swine influenza virus and uses thereof
granted -
US 9550742
11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopamine D2 receptor antagonists
granted -
US 9546151
VMAT inhibitory compounds
granted -
US 9545431
Isolated recombinant cDNA
granted -
US 9539220
Methods for treating suicidal ideation
granted -
US 9540427
Peptide-based stat inhibitor
granted -
US 9540471
Nitric oxide-releasing diazeniumdiolated polyvinylpyrrolidone-based polymers, and compositions, medical devices, and uses thereof
granted -
US 9540642
Compositions and methods for controlling arthropod parasite and pest infestations
granted -
US 9540415
Inhibitors of the farnesoid X receptor and uses in medicine
granted -
US 9534008
Small molecule compounds that control plant- and insect-pathogenic nematodes
granted -
US 9533031
Yeast-MUC1 immunotherapeutic compositions and uses thereof
granted -
US 9532989
Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines
granted -
US 9534041
Monoclonal antibodies that neutralize a norovirus
granted -
US 9534007
Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
granted -
US 9534044
Alpha-synuclein antibodies and uses thereof
granted -
US 9527903
Engineered antibody constant domain molecules
granted -
US 9528094
Attenuated African swine fever virus vaccine based in the deletion of MGF genes
granted -
US 9526777
Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
granted -
US 9526739
Compositions and methods to treat cardiac diseases
granted -
US 9522871
Preparation of (R,R)-fenoterol and (R,R)-or (R,S)-fenoterol analogues and their use in treating congestive heart failure
granted -
US 9522955
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
granted -
US 9522948
GP100-specific T cell receptors and related materials and methods of use
granted -
US 9517243
Beta-mannosylceramide and stimulation of NKT cell anti-tumor immunity
granted -
US 9517224
Methods of treating patients infected with HIV and HTLV
granted -
US 9518080
Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
granted -
US 9513287
High affinity monoclonal antibodies for detection of shiga toxin 2
granted -
US 9511075
Targeting NCCA-ATP channel for organ protection following ischemic episode
granted -
US 9511103
AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
granted -
US 9513289
Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
granted -
US 9505812
Plasmodium falciparum antigens
granted -
US 9506041
Delivery of packaged RNA to mammalian cells
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory